Abstract

Diabetes Mellitus is a non-transmissible chronic disease, characterized by increased circulating glucose levels and caused by the destruction of pancreatic beta cells or the interruption of insulin production. It is a complex pathology that impairs the productivity, quality of life and the survival rates of patients. Considering that the periodic and appropriate treatment decreases and/or delays the probability of developing complications, the purpose of this study is to identify the most prescribed therapy for patients with DM1 assisted by the Specialized Component of Pharmaceutical Services on the state of Piauí, Brazil. It is an analytical cross-sectional study that uses a quantitative approach. The research focuses on the DM1 patients assisted by the SCPS, the organization responsible for dispensing high cost insulin. The research was performed in 2017, when 208 medical records were analyzed. This study was approved by Human Research Ethics Committee of the Faculdade Integral Diferencial (FACID) of DeVry Brasil group under protocol nº 68644717.2.0000.5211. The most prescribed insulinization regimens are Glargine associated with Aspart 38% (n=79), followed by Glargine with Glulisine 32% (n=67) and by Glargine with Insulin Lispro (n=44). The correct treatment of DM1 involves the use of two types of different insulins to simulate the basal secretion and the insulin peak post-meal. It is evidenced that the concomitant use of two types of insulins is a more effective treatment to insulin-dependent diabetics. The association of Glargine and Aspartate was the most prescribed in this study, and it was observed that patients that use only one type presented undesirable effects.

Keywords

insulin, diabetes mellitus, pharmaceutical care